-
Mashup Score: 0ctDNA and beyond to serve immunotherapy - 21 hour(s) ago
Recent findings consolidate the role of liquid biopsy in the field, but prospective research is needed
Source: dailyreporter.esmo.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 59ctDNA and beyond to serve immunotherapy - 2 day(s) ago
Recent findings consolidate the role of liquid biopsy in the field, but prospective research is needed
Source: dailyreporter.esmo.orgCategories: General Medicine News, Oncologists1Tweet-
Recent findings consolidate the role of #LiquidBiopsy in the field of #immunotherapy, but prospective research is needed. Read the analysis by @UmbertoMalapel1 based on recent results presented during #ESMOImmuno24 #ESMODailyReporter 📌https://t.co/nlXCH6LL1t https://t.co/y9e39r33ob
-
-
Mashup Score: 7Sacituzumab govitecan failed to improve OS in pre-treated UC - 18 day(s) ago
Despite being active in this disease setting, the antibody-drug conjugate was associated to high rates of neutropenic complications
Source: dailyreporter.esmo.orgCategories: General Medicine News, Oncologists1Tweet-
#ESMOAsia24: The results of the phase III TROPiCS-04 study reveal that sacituzumab govitecan, while active in pre-treated pts w/ adv #UrothelialCarcinoma, did not significantly improve OS or PFS compared to platinum-based chemotherapy. #ESMODailyReporter https://t.co/FtNUMsDDlY https://t.co/X2LssmDdQs
-
-
Mashup Score: 3Mixed results for additional immunotherapy in stage III NSCLC - 24 day(s) ago
Different combinations of immunotherapy agent and radiotherapy or chemoradiotherapy were tested in some patient populations in two studies
Source: dailyreporter.esmo.orgCategories: General Medicine News, Oncologists1Tweet-
Different combinations of #immunotherapy agent and radiotherapy or chemoradiotherapy were tested in some patient populations in two studies presented at #ESMOImmuno24 #ESMODailyReporter https://t.co/38HKGz9xrY @AlastairGreyst2 https://t.co/dM5C3GeK0A
-
-
Mashup Score: 0
Next steps for research include personalising regimens and learning how to predict response and toxicity
Source: dailyreporter.esmo.orgCategories: General Medicine News, Oncologists1Tweet-
#ESMOImmuno24: > 40% of pts w/ resectable stage III #melanoma face recurrence post-treatment. Lack of OS benefits w/ adjuvant ICIs led to exploring new approaches. Future steps: #PersonalisedPlans & prediction of response/toxicities. #ESMODailyReporter 📌https://t.co/5wCswa0fld https://t.co/W0O0IuP1vJ
-
-
Mashup Score: 7Liquid biopsies to tailor immunotherapy: New peomising data - 24 day(s) ago
Studies explore the prognostic & predictive values of ctDNA tumour fraction and single-cell RNA sequencing of peripheral blood mononuclear cells
Source: dailyreporter.esmo.orgCategories: General Medicine News, Oncologists1Tweet-
Studies presented at #ESMOImmuno24 explore the prognostic and predictive values of circulating tumour DNA tumour fraction and single-cell RNA sequencing of peripheral blood mononuclear. #ESMODailyReporter 📌https://t.co/F1rPXYQpiE @ChristianRolfo https://t.co/ZWpaorHPOf
-
-
Mashup Score: 9New data on gut microbiome's role in immunotherapy toxicity - 25 day(s) ago
Results underline the need to further characterise dysbiosis, and to develop diagnostic and actionable tools for mainstream integration
Source: dailyreporter.esmo.orgCategories: General Medicine News, Oncologists1Tweet-
The impact of #GutMicrobiota on #immunotherapy response and resistance has been established, but studies presented at #ESMOImmuno24 highlight important associations between microbiota and immunotherapy-related toxicities.  #ESMODailyReporter 📌https://t.co/ipZmd9Sh3w https://t.co/HRX65wbwcN
-
-
Mashup Score: 13Are we close to personalise immunotherapy? - 25 day(s) ago
Tackling the T-cell receptor challenge with vast datasets and cutting-edge high-throughput methods may pave the way for advances in the field
Source: dailyreporter.esmo.orgCategories: General Medicine News, Oncologists1Tweet-
#ESMOImmuno24: According to the 2024 ESMO Immuno-Oncology Awardee, @Schumacher_lab, tackling the T-cell receptor challenge w/ vast datasets and cutting-edge high-throughput methods may pave the way for advances in #immunotherapy. #ESMODailyReporter 📌https://t.co/FyknBm6pAB https://t.co/KKeN3BvUdT
-
-
Mashup Score: 5Real-world evidence has a place in cancer immunotherapy - 25 day(s) ago
However, some challenges still limit its implementation in clinical practice
Source: dailyreporter.esmo.orgCategories: General Medicine News, Oncologists1Tweet-
#ESMOImmuno24: Real-world evidence has a place in #CancerImmunotherapy. However, some challenges still limit its implementation in #ClinicalPractice. #ESMODailyReporter #ESMO-GROW @DoniaMarco 📌https://t.co/OMpGFaycJ6 https://t.co/jFtJwQhc8G
-
-
Mashup Score: 10
Study confirms favourable safety profiles and encouraging efficacy of an anti-claudin 18.2 antibody-drug conjugate
Source: dailyreporter.esmo.orgCategories: General Medicine News, Oncologists1Tweet-
Data presented at #ESMOAsia24 highlight the potential of IBI343, an anti-claudin 18.2 antibody-drug conjugate, in treating #AdvancedPancreatic ductal #adenocarcinoma (#PDAC) with positive CLDN18.2 expression. 📌https://t.co/lnWuiJylqE #PrecisionOncology #ESMODailyReporter https://t.co/Q6mgRi1wgC
-
https://t.co/UfTkbSlZup